Take-home message: Are we "off target"?

Drug News and Perspectives

Volumn 20, Issue 5, 2007, Pages 345-351

  Khurdayan, Valeria K ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; AZD 1152; BEVACIZUMAB; BIOLOGICAL MARKER; CAT 5001; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EXHERIN; GEFITINIB; IMATINIB; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; KU 0059436; MLN 8054; MORAB 009; NERVE CELL ADHESION MOLECULE; PHA 739358; PLASMINOGEN ACTIVATOR INHIBITOR; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TORISEL; UNCLASSIFIED DRUG; WX 671;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; HYPOPHYSITIS; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY CARCINOMA; MELANOMA; METASTASIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 34548328282     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Verweij, J. "Off target". 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, NDDO Honorary Lecture 2007.
2. Fu, J., Bian. M., Jiang, Q. and Zhang, C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007, 5(1): 1-10.
3. Schellens, J.H.M. Aurora kinase inhibitors. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O201.
4. Morgan, R.A., Dudley, M.E., Wunderlich, J.R. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314: 126-9.
5. Sherry, R.M. and Rosenberg, S.A. The development of effective cell transfer immunotherapy for patients with cancer. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O102).
6. Rini, B. Angiogenesis inhibitors in the treatment of advanced renal cell cancer. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O301.
7. Perotti, A. et al. Final results of the phase Ib/II study of the N-cadherin (N-cad) antagonist ADH-1 in patients with solid tumors. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O204.
8. Schmalix, W.A., Schneider, A., Setyono-Han, T.H. and Foekens, J. Additive effects on tumor spread in various rat cancer models of combining cytotoxic treatments with the oral uPA/serine protease inhibitor WX-671. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst P207.
9. Seera, S., Ramarao, C., Kousar, J., Prabhakaran, P.S., Bapsy, P.P. and Attili, S. To evaluate the levels of MMP expression in patients with breast cancer and correlate with the hormonal receptor (HR) and Her2/neu receptor status. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst P716.
10. Kogan, E. and Sagindikova, E. Matrix metalloproteinases and angiogenesis in various morphological types of precancer of the lung in patients from Semipalatinsk region of Kazakhstan with high radiation level. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst P501.
11. Fojo, T. Cancer stem cell hypothesis: An inadequate explanation for drug resistance. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O701.
12. Hassan, R. and Pastan, I. Antibody-based therapies targeting the tumor antigen mesothelin. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O703.
13. de Bono, J., Boss, D., Fong, P., Roelvink, M., Yap, T. and Tutt, A. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O704.
14. DiMartino, J.F. and deSauvage, F. Inhibition oj Hedgehog signaling as a novel mechanism of cancer therapy. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O705.
15. Doroshow, H. Phase "0" trials. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O802.
16. Kummar, S. et al. Compressing drug development timelines in oncology using phase '0' trials. Nat Reviews 2007, 7(2): 131-9.
17. Palmeri, S., Pignatti, F. and Jonsson, B. Role of biomarkers in the regulatory process. 5th Intl Symp Targeted Anticancer Ther (March 8-10, Amsterdam) 2007, Abst O801.